124
Participants
Start Date
December 31, 2006
Primary Completion Date
March 31, 2010
Study Completion Date
August 31, 2011
AS703569
"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
AS703569
"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
Hospitaux Universitaires, Geneva
Haematologie UZ Gasthuisberg, Leuven
Kantonsspital St Gallen, Sankt Gallen
Policlinico Sant'Orsola Malpighi, Bologna
CTRC at the UT Health Science Center at San Antonio, San Antonio
Mont-Godinne University Hospital (UCL), Yvoir
Universitatsklinik Frankfurt, Frankfurt am Main
Technische Universitat Munchen, München
Medizinische Universitatsklinik, Ulm
Kantonsspital Basel, Basel
Lead Sponsor
EMD Serono
INDUSTRY